Zaramella M G, Vallini R, Tiribelli C
Liver. 1985 Jun;5(3):129-33. doi: 10.1111/j.1600-0676.1985.tb00227.x.
Following intravenous administration of 500 mg/kg b.wt. galactose, Galactose Elimination Capacity (GEC, mg/min/kg) was determined in 24 subjects with chronic non-cirrhotic liver disease (CLD), 33 with liver cirrhosis and 11 controls. GEC was significantly (P less than 0.01) reduced in both CLD and cirrhosis. A statistically significant difference (P less than 0.01) was present between these two groups. Following the plasma disappearance curve at concentrations below 1.25 mmol/l, at which the extraction coefficient is assumed to be equal to one, the "Efficient Hepatic Blood Flow" (EHBF, ml/min) was determined in 11 consecutive cirrhosis patients, seven patients with CLD and 11 controls. EHBF was normal or slightly reduced in CLD as compared to controls (1046 +/- 216 vs. 1471 +/- 156 ml/min, mean +/- SEM, n.s.) whereas it was markedly reduced in cirrhosis (846 +/- 96 ml/min, mean +/- SEM, p less than 0.001). Interestingly, a significant linear correlation (r = 0.757, p less than 0.001) was present between EHBF and the plasma clearance of sulfobromophthalein. No correlation was present, on the other hand, between the value of GEC and that of EHBF. These data indicate that after a single intravenous injection of galactose, the hepatic blood flow passing through the enzymatically active parts of the liver (i.e. excluding shunts) can be measured.
给24名慢性非肝硬化性肝病（CLD）患者、33名肝硬化患者和11名对照者静脉注射500mg/kg体重的半乳糖后，测定了半乳糖清除能力（GEC，mg/min/kg）。CLD组和肝硬化组的GEC均显著降低（P<0.01）。这两组之间存在统计学显著差异（P<0.01）。在血浆浓度低于1.25mmol/l时跟踪血浆消失曲线，此时提取系数假定为1，在11名连续的肝硬化患者、7名CLD患者和11名对照者中测定了“有效肝血流量”（EHBF，ml/min）。与对照相比，CLD患者的EHBF正常或略有降低（1046±216 vs. 1471±156ml/min，均值±标准误，无显著性差异），而肝硬化患者的EHBF则显著降低（846±96ml/min，均值±标准误，P<0.001）。有趣的是，EHBF与磺溴酞钠的血浆清除率之间存在显著的线性相关性（r = 0.757，P<0.001）。另一方面，GEC值与EHBF值之间无相关性。这些数据表明，单次静脉注射半乳糖后，可以测量流经肝脏酶活性部位的肝血流量（即不包括分流）。
